A breakthrough in Alzheimer's treatment appears imminent as another drug has demonstrated the ability to slow down the progression of the disease, marking the second such advancement within a year.

Eli Lilly reported encouraging results for their drug called donanemab, revealing its potential to significantly slow down the advancement of Alzheimer's by nearly one-third. Donanemab operates on a similar principle as Biogen’s lecanemab, a drug that garnered global attention for its remarkable efficacy in combating the disease.